About 280 million people suffer from depression as the most common neurological disorder
and the most common cause of death worldwide. Exercise with serotonin released in the …

Psychiatric disorders and sleep problems are both common, with an estimated prevalence in
12 months of about 30% for any of the Diagnostic and Statistical Manual of Mental …

The monoamine hypothesis has been the prevailing hypothesis of depression over the last
several decades. It states that depression is associated with reduced monoamine function …

GLYX-13 is a putative NMDA receptor modulator with glycine-site partial agonist properties
that produces rapid antidepressant effects, but without the psychotomimetic side effects of …

Mood disorders are recurrent/chronic diseases with variable clinical remission rates.
Available antidepressants are not effective in all patients and often show a relevant …

The orexin (hypocretin) system comprises two neuropeptides (orexin-A and orexin-B) and
two G-protein coupled receptors (the orexin type 1 and the orexin type 2 receptor). The …

Background Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated
antidepressant effects in a previous exploratory study in patients with major depressive …

Mood disorders, including major depression, bipolar disorder, and seasonal affective
disorder, are debilitating disorders that affect a significant portion of the global population …

Stress-related disorders, such as mood disorders and posttraumatic stress disorder (PTSD),
are more common in women than in men. This sex difference is at least partly due to the …

Background Neurophysiological and behavioral processes regulated by hypocretin (orexin)
are severely affected in depression. However, alterations in hypocretin have so far not been …